Experimental combo aims to reignite immune attack on lung cancer
NCT ID NCT07322341
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether combining SX-682 (a drug that blocks certain immune-suppressing proteins) with atezolizumab (an immunotherapy) can shrink tumors in people with advanced non-small cell lung cancer that has worsened after chemotherapy and immunotherapy. About 32 adults will receive both drugs and be monitored for tumor response. The goal is to see if this combination can help the immune system fight the cancer more effectively.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SX-682 and atezolizumab
What this could lead to
If it works, this combination could offer a new treatment option for people with advanced lung cancer who have run out of standard therapies.
What could go wrong
This is a small, early-phase trial with only 32 participants, so results may not apply to everyone. The drugs may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••